- Home
- BLNK vs AVIR Comparison
BLNK vs AVIR Comparison
Compare BLNK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- AVIR
- Stock Information
- Founded
- BLNK 2009
- AVIR 2012
- Country
- BLNK United States
- AVIR United States
- Employees
- BLNK N/A
- AVIR N/A
- Industry
- BLNK Industrial Specialties
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- BLNK Consumer Discretionary
- AVIR Health Care
- Exchange
- BLNK Nasdaq
- AVIR Nasdaq
- Market Cap
- BLNK 77.3M
- AVIR 273.0M
- IPO Year
- BLNK N/A
- AVIR 2020
- Fundamental
- Price
- BLNK $0.97
- AVIR $3.73
- Analyst Decision
- BLNK Buy
- AVIR Hold
- Analyst Count
- BLNK 8
- AVIR 1
- Target Price
- BLNK $2.61
- AVIR $6.00
- AVG Volume (30 Days)
- BLNK 4.3M
- AVIR 407.1K
- Earning Date
- BLNK 08-06-2025
- AVIR 08-06-2025
- Dividend Yield
- BLNK N/A
- AVIR N/A
- EPS Growth
- BLNK N/A
- AVIR N/A
- EPS
- BLNK N/A
- AVIR N/A
- Revenue
- BLNK $109,383,000.00
- AVIR N/A
- Revenue This Year
- BLNK N/A
- AVIR N/A
- Revenue Next Year
- BLNK $31.15
- AVIR N/A
- P/E Ratio
- BLNK N/A
- AVIR N/A
- Revenue Growth
- BLNK N/A
- AVIR N/A
- 52 Week Low
- BLNK $0.63
- AVIR $2.46
- 52 Week High
- BLNK $3.75
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- BLNK 55.64
- AVIR 74.60
- Support Level
- BLNK $0.88
- AVIR $3.63
- Resistance Level
- BLNK $1.10
- AVIR $3.78
- Average True Range (ATR)
- BLNK 0.08
- AVIR 0.14
- MACD
- BLNK 0.00
- AVIR 0.02
- Stochastic Oscillator
- BLNK 56.43
- AVIR 100.00
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).